NCT04741438 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT04741438
Title	Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype (RAR-Immune)
Acronym	RAR-Immune
Recruitment	Unknown status
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	Centre Leon Berard
Indications	inflammatory myofibroblastic tumor angiosarcoma malignant epithelioid hemangioendothelioma sarcoma fibrosarcoma epithelioid sarcoma alveolar soft part sarcoma perivascular epithelioid cell tumor malignant peripheral nerve sheath tumor clear cell sarcoma desmoplastic small round cell tumor solitary fibrous tumor/hemangiopericytoma extraskeletal myxoid chondrosarcoma chordoma
Therapies	Ipilimumab + Nivolumab Pazopanib
Age Groups:	adult \| senior
Covered Countries	FRA

Additional content available in CKB BOOST